Kinfo
Allurion Technologies Inc. logo

Allurion Technologies Inc.

ALURNYSEHealthcare·US · USD
$4.72
-0.78 (-14.27%)
Prices as of July 10, 2026 · market closed

Price

Key statistics

Valuation
Market cap4.72M USD
Enterprise value82.04M USD
Trailing P/E32.88
Forward P/E-3.23
PEG ratio-0.06
Price / sales0.32
Price / book-0.05
Profitability
Gross margin41.70%
Operating margin-126.60%
Profit margin-264.74%
Return on assets-66.80%
Return on equity37.25%
Income (TTM)
Revenue12.60M USD
Gross profit6.64M USD
EBITDA-27.05M USD
Net income-33.35M USD
Diluted EPS-$3.96
Rev. growth (YoY)-47.20%
Balance sheet
Total cash5.06M USD
Total debt78.25M USD
Debt / equity-1.00
Current ratio0.30
Book value / share-$5.20
Cash flow (TTM)
Operating cash flow-22.70M USD
Levered free cash flow-13.37M USD
Shares & price
Shares outstanding999.63K
Float14.70M
Held by institutions1.18%
Beta-0.17
50-day MA$10.37
200-day MA$17.98
52-week high$49.95
52-week low$2.67
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-05-15-5.10-6.90−35.29%2026-03-30-9.45-5.44+42.43%2025-11-12-36.75-17.75+51.70%2025-09-2250.6848.71−3.89%2025-08-19-13.35-13.10+1.87%
About Allurion Technologies Inc.

Allurion Technologies Inc. is a healthcare-focused company dedicated to developing non-invasive medical devices and technology solutions aimed at promoting weight loss and healthy living. The cornerstone of Allurion's offerings is the Elipse Balloon, a swallowable, intragastric balloon designed to aid in weight loss without the need for surgery or endoscopic procedures. This innovative device gradually inflates within the stomach, providing a temporary sense of fullness to patients, which helps reduce food intake. Allurion operates primarily within the medical technology and wellness sectors, targeting a global market that includes hospitals, clinics, and wellness centers. With obesity being a significant health concern worldwide, Allurion's non-surgical solutions garner attention for their potential impact on improving patient outcomes while reducing healthcare costs associated with obesity-related conditions. The company continues to evolve its technological platforms, incorporating digital tools to monitor and support patients throughout their weight loss journey, cementing its position in the intersection of health, technology, and consumer healthcare markets.

Sector
Healthcare
Industry
Medical Devices
CEO
Dr. Shantanu K. Gaur M.D.
Employees
38
Headquarters
Natick, MA, United States

Frequently asked questions about Allurion Technologies Inc.